FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 1AD | $0.01 | 0.00% | $0.02 | $0.00 |
|
||
| ACR | $0.02 | 0.00% | $0.03 | $0.01 |
|
||
| ACW | $0.04 | 0.00% | $0.07 | $0.02 |
|
||
| ADO | $0.01 | 0.00% | $0.03 | $0.01 |
|
||
| AFP | $3.19 |
|
$3.37 | $2.20 |
|
||
| AGN | $0.26 |
|
$0.89 | $0.19 |
|
||
| ARX | $0.70 |
|
$0.80 | $0.35 | 141.7 |
$0.82 |
|
| AVH | $1.09 |
|
$3.38 | $1.00 |
$1.275 |
|
|
| BIO | $0.43 |
|
$0.72 | $0.39 | 28.7 |
$1.00 |
|
| BOT | $0.12 |
|
$0.54 | $0.10 |
|
||
| COV | $0.61 | 0.00% | $0.90 | $0.31 |
|
||
| CSL | $152.19 |
|
$275.79 | $150.21 | 16.0 |
$207.477 |
|
| CUV | $10.72 |
|
$14.00 | $9.41 | 15.4 |
$16.50 |
|
| DXB | $0.51 |
|
$0.79 | $0.34 |
|
||
| GSS | $0.13 |
|
$0.69 | $0.13 |
$0.55 |
|
|
| IDT | $0.05 | 0.00% | $0.12 | $0.05 |
|
||
| ILA | $0.39 |
|
$0.63 | $0.12 |
|
||
| IMM | $0.38 |
|
$0.47 | $0.22 |
$1.075 |
|
|
| IMU | $0.26 |
|
$0.46 | $0.01 |
$0.82 |
|
|
| IVX | $0.08 | 0.00% | $0.20 | $0.08 |
|
||
| LGP | $0.13 | 0.00% | $0.15 | $0.10 |
|
||
| MAP | $0.09 | 0.00% | $0.27 | $0.07 |
$0.21 |
|
|
| MSB | $2.45 |
|
$3.31 | $1.52 | -86.1 |
$4.45 |
|
| MVP | $0.48 |
|
$0.94 | $0.42 |
$0.84 |
|
|
| MYX | $2.67 |
|
$7.31 | $2.60 |
|
||
| NEU | $13.57 |
|
$22.99 | $8.61 | 98.7 |
$24.567 |
|
| NUZ | $0.10 | 0.00% | $0.19 | $0.08 |
$0.28 |
|
|
| OCC | $0.94 |
|
$1.70 | $0.86 |
|
||
| OSL | $0.69 |
|
$2.09 | $0.00 |
|
||
| PAR | $0.31 | 0.00% | $0.66 | $0.26 |
$0.65 |
|
|
| PER | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| PNV | $0.93 |
|
$2.07 | $0.92 | 40.4 |
$1.977 |
|
| PYC | $1.48 |
|
$1.76 | $0.85 |
$2.30 |
|
|
| RAC | $2.25 |
|
$4.90 | $0.92 |
|
||
| RCE | $0.59 |
|
$0.73 | $0.28 |
|
||
| SNT | $0.03 | 0.00% | $0.10 | $0.02 |
$0.06 |
|
|
| SPL | $0.48 |
|
$0.50 | $0.08 |
|
||
| TLX | $9.08 |
|
$31.97 | $9.05 | -558.0 |
$27.24 |
|
| TRP | $0.19 |
|
$0.48 | $0.17 |
|
||
| VIT | $0.05 | 0.00% | $0.14 | $0.05 |
|
||
| ZNO | $0.07 | 0.00% | $0.18 | $0.03 |
|
17.1% Previous Stories
Dr Boreham’s Crucible: Cleo Diagnostics
Aug 30 2023
Tim Boreham shines a light on freshly listed Cleo Diagnostics, in search of an effective diagnostic tool for ovarian cancer
Breaking Boundaries: Medical Psychedelics
Aug 21 2023
Australia is the first country in the world to legalise the use of psychedelic drugs for mental illness
Momentum Keeps Building For Avita Medical
Aug 15 2023
Brokers raise target prices for Avita Medical following second quarter results amidst anticipation of exciting prospects in the outlook period
Dr Boreham’s Crucible: IDT Australia
Aug 14 2023
Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market
Treasure Chest: Less Smooth Road Ahead For CSL
Aug 01 2023
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea relates to CSL
Dr Boreham’s Crucible: Telix Pharmaceuticals
Jul 31 2023
Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports
Dr Boreham’s Crucible: Arovella Therapeutics
Jul 17 2023
Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics
Dr Boreham’s Crucible: PolyNovo
Jul 06 2023
Skin repair specialist PolyNovo remains confident in its firm growth path ahead
CSL Disappoints But Brokers Retain The Faith
Jun 15 2023
CSL’s trading and guidance fell -12% short of consensus forecasts but most brokers hold the faith
Dr Boreham’s Crucible: Dimerix
Jun 07 2023
A positive trial result could put a rocket on shares in Dimerix, reports Tim Boreham, but investors won’t know the answer until early 2024